Condition

Chronic Lymphocytic Leukemia (CLL) clinical trials and research

• 22Clinical trials
• 3NIH research projects
• 18Countries

Newest Chronic Lymphocytic Leukemia (CLL) clinical trials

All recruiting trials (22)

• Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

  This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.

  Recruiting European Research Initiative on CLL · Milan · NCT07774390

• Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

  This study checks whether brain health and well‑being differ for people with leukemia who are starting or on TKI therapy compared with similar individuals without cancer or TKI exposure.

  Recruiting University of Rochester · Rochester, New York · NCT07638007

• BTK degrader plus BCL-2 inhibitor in untreated CLL/SLL

  This phase 2 study tests whether the BTK degrader BGB-16673 together with sonrotoclax can help people with newly diagnosed CLL/SLL.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07508995

• Immune profiling during first-line pirtobrutinib treatment for CLL/SLL

  This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.

  Recruiting Early Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07428707

• NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy

  NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.

  Recruiting at 43 sites Phase 2 Nurix Therapeutics, Inc. · Phoenix, Arizona and 42 other locations · NCT07221500

• GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia

  This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Zhengzhou, Henan and 1 other locations · NCT07205315

• Quality of life and symptom changes over two years in adults with CLL or SLL starting targeted therapy

  This study will see how quality of life, fatigue, and symptoms change over two years for adults with CLL or SLL who start treatment with a BTK inhibitor versus a BCL2 inhibitor.

  Recruiting H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07030400

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• Long-term safety of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788639

• Testing UB-VV111 with and without Rapamycin for B-cell cancers

  This study is testing a new treatment called UB-VV111, with and without another drug called rapamycin, to see if it can help people with certain types of B-cell cancers that haven't responded to other treatments.

  Recruiting at 9 sites Phase 1 Umoja Biopharma · Duarte, California and 8 other locations · NCT06528301

• Registry platform for patients with blood cancers in Germany

  This study is setting up a national registry to collect information from patients with blood cancers in Germany to see how well different treatments work and what patients need.

  Recruiting iOMEDICO AG · Freiburg im Breisgau · NCT06043011

• Testing IDP-121 in patients with certain blood cancers

  This study is testing a new treatment called IDP-121 to see if it can help people with certain blood cancers, like multiple myeloma and lymphoma, feel better and live longer.

  Recruiting at 11 sites Phase 1/2 IDP Discovery Pharma S.L. · Santander, Cantabria and 10 other locations · NCT05908409

• Observing heart rhythms in patients treated with BTK inhibitors or venetoclax

  This study is testing how Bruton’s tyrosine kinase inhibitors affect heart rhythms in people with chronic lymphocytic leukemia and comparing it to those taking venetoclax to see if there are any risks.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05724121

• Observational study of acalabrutinib for chronic lymphocytic leukaemia in the UK

  This study looks at how well acalabrutinib works for people with chronic lymphocytic leukaemia in the UK by collecting real-life treatment data from their medical records.

  Recruiting at 29 sites AstraZeneca · Aylesbury and 28 other locations · NCT05557695

• Combination of zanubrutinib and venetoclax for treating chronic lymphocytic leukemia

  This study is testing if combining the drugs zanubrutinib and venetoclax can help adults with chronic lymphocytic leukemia who have already been treated feel better and manage their disease.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT05168930

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Assessing the effects of venetoclax and obinutuzumab in adults with recurring chronic lymphocytic leukemia

  This study is testing if a combination of two medications, venetoclax and obinutuzumab, can help adults with recurring chronic lymphocytic leukemia feel better after their previous treatments.

  Recruiting at 50 sites Phase 2 AbbVie · La Jolla, California and 57 other locations · NCT04895436

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

• Combining Venetoclax, Rituximab, and Ibrutinib for Treating Chronic Lymphocytic Leukemia

  This study is testing if adding ibrutinib to a year-long treatment of venetoclax and rituximab can help people with newly diagnosed Chronic Lymphocytic Leukemia reach a state where the disease is undetectable.

  Recruiting Phase 2 IRCCS San Raffaele · Milan, MI · NCT04758975

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

• Venetoclax for chronic lymphocytic leukemia in real-world care

  This study will see how well venetoclax works and how patients do when it is used alone or with other common CLL drugs in routine clinical care.

  Recruiting at 5 sites AbbVie · Sankt Pölten, Lower Austria and 73 other locations · NCT03342144

• Collecting samples to study hairy cell leukemia and develop new cancer treatments

  This study is collecting samples from people with hairy cell leukemia and healthy volunteers to see if new treatments can be developed to better fight this type of cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01087333

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Why some early B‑cell changes progress to chronic lymphocytic leukemia (CLL)

  This work looks at inherited gene variants and chemical tags on DNA to find which people with monoclonal B‑cell lymphocytosis (MBL) are more likely to develop CLL.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11181017

• Investigating genetic factors linked to chronic lymphocytic leukemia (CLL)

  This study is looking at how certain rare genetic changes, especially in the ATM gene, might make some people more likely to develop chronic lymphocytic leukemia (CLL), and it's inviting patients with known ATM gene changes to help us learn more about how these genetics relate to CLL and family cancer history.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11059143

• Investigating the genetic factors that lead to chronic lymphocytic leukemia from its precursor state.

  This study is looking at how certain genes might help us understand why some people with a condition called monoclonal B-cell lymphocytosis (MBL) might develop chronic lymphocytic leukemia (CLL) later on, especially focusing on African Americans, so we can find ways to better predict and prevent the disease.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10914019

Related topics

Quick answers

How many Chronic Lymphocytic Leukemia (CLL) clinical trials are recruiting right now?

22, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in United States (15 trials), Italy (6 trials), United Kingdom (5 trials), Spain (4 trials), Poland (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1: 3, Early Phase 1: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →